D4-PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of D4-PHARMA is 1.9% (moderate). The 2025 annual accounts show equity of €167,820 and a net result of €15,203. Equity is shrinking by about 3% per year across the filed financial years. Its solvency ranks better than 20% of 12,578 sector peers (NACE 47, financial year 2025). The company has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 31 days late
2025
28-08
NBB filing
Annual accounts filed
financial year 2024 · full format · 28 days late
2024
31-12
Financial
Back to profitnet €85,204
Net result €85,204 after 2 loss-making years.
30-08
NBB filing
Annual accounts filed
financial year 2023 · full format · 30 days late
2023
14-09
NBB filing
Annual accounts filed
financial year 2022 · full format · 45 days late
2022
17-10
NBB filing
Annual accounts filed
financial year 2021 · full format · 78 days late
2021
23-07
NBB filing
Annual accounts filed
financial year 2020 · full format
2020
31-12
Financial
Back to profitnet €53,170
Net result €53,170 after 2 loss-making years.
31-12
Financial
Liquidity more than doubledcurrent ratio 5.53
Current ratio from 1.98 to 5.53; short-term debt falls from €174,756 to €55,429.
08-07
NBB filing
Annual accounts filed
financial year 2019 · full format
2019
31-12
Financial
Weakest financial yearnet -€54,352
Net result drops to -€54,352, the lowest in the series; recovery starts the following year.
19-07
NBB filing
Annual accounts filed
financial year 2018 · full format
2018
29-08
NBB filing
Annual accounts filed
financial year 2017 · full format · 29 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.